A new study launched in the UK should give some answers as to why biological treatment does not work in around a third of patients with rheumatoid arthritis.
Run by an NIHR Translational Research Partnership in partnership with Janssen the study will explore the molecular pathways that determine whether people with rheumatoid arthritis will benefit from treatment with anti-TNF therapies or not.
The study should provide information that will enable better targeting of anti-TNF therapies and potentially lead to the development of new and alternative treatments the NIHR said in a statement.